ATP disodium paʻakai CAS 987-65-5

CAS:987-65-5

Maʻemaʻe:99%

ʻAno Molekala:C10H17N5NaO13P3

Kaumaha Molekala:531.18

EINECS:213-579-1

Ka wā mālama:2 makahiki

Nā huaʻōlelo like:ADENOSINETRIPHOSPHATEDISODIUM; ADENOSINETRIPHOSPHATE,DISODIUMSALT; ADENYLPYROPHOSPHORICACIDDISODIUMSALT; ADENOSINE-5′-TRIPHOSPHATEHYDRATEDISODIUMSALT; ADENOSINE-5′-TRIPHOSPHATENA2-PAʻakai; ADENOSINE-5′-TRIPHOSPHORICACID,DISODIUM; ADENOSINE-5′-TRIPHOSPHORICACIDDISODIUMDIHYDROGENSALT; ADENOSINE5′-TRIPHOSPHORICACIDDISODIUMSALT

Waiho i kāu leka

Huahana Huahana

Hoʻoiho

Huahana Huahana

He aha ka ATP disodium salt CAS 987-65-5?

ʻO ka paʻakai disodium ATP he metabolite o adenosine, he multifunctional nucleoside triphosphate i hoʻohana ʻia ma ke ʻano he coenzyme no ka hoʻoili ʻana o ka ikehu intracellular i loko o nā cell. Lawe ʻo ia i ka ikehu kemika i loko o nā cell no ka metabolism. Hoʻohana ʻia ka paʻakai disodium ATP e synthesize ribose-modified deoxyadenosine diphosphate analogs like P2Y1 receptor ligands.

Hōʻike

Ka nana aku	ʻO ka pauka keʻokeʻo a i ʻole ka pauka keʻokeʻo a i ʻole ka pauda kristal, hygroscopic.
Nui ʻāpana	＞95% hele ma 80 mesh.
pH	2.5～3.5
Ka hikiwawe	Hiki i ka wai; hiki ʻole ke hoʻoheheʻe ʻia i ka ethanol & ether.
Oder	Oderless
ʻAno wai	6.0%~12.0%
Klorida	≤0.05%
Paakai hao	≤0.001%
Nā metala kaumaha	≤0.001%
Ke alakaʻi	≤2.0ppm
Arsenic	≤1.0ppm

Palapala noi

1. Hoʻohana i ka noiʻi ʻenehana a me ka ʻepekema
(1) ʻO nā mea waiwai waiwai: hoʻohui ʻia i nā huahana mālama ʻili anti-kahiko, hiki iā ia ke hoʻomaikaʻi i ka elasticity o ka ʻili a me ka glossiness ma ka hoʻoulu ʻana i ka metabolism ikehu cell.
(2) Mea hoʻohui meaʻai: hoʻohana ʻia ma ke ʻano he mea hoʻonui meaʻai i nā mea inu haʻuki a me nā meaʻai hana e hoʻopiha koke i ka ikehu.
2. Nā wahi lapaʻau lapaʻau
(1) ʻO nā maʻi ʻōnaehana cardiovascular: hoʻohana ʻia no ka hāʻule ʻana o ka naʻau, myocarditis, myocardial infarction a me cerebral arteriosclerosis, etc., ma ka hoʻomaikaʻi ʻana i ka myocardial energy metabolism a me ka hoʻonui ʻana i ke kahe koko ma kahi o 30%), e hoʻomaha ana i nā hōʻailona myocardial ischemia. No ka laʻana, i nā poʻe maʻi me ka infarction myocardial acute, hiki i ka ATP disodium ke hoʻopōkole i ka manawa hāʻule o ST a hoʻemi i ka waiwai kiʻekiʻe o ka spectrum enzyme myocardial.
(2) ʻO nā maʻi maʻi Nervous: kōkua kōkua i ka sequelae o ka cerebral hemorrhage, ka pōʻino o ka lolo a me ka holomua muscular atrophy, ma ke komo ʻana i ka pale koko-lolo (permeability e pili ana i 65%), e hoʻoikaika ana i ka hoʻoponopono ʻana o ka nerve cell membrane a me ke kaʻina hana nerve, a me ka hoʻomaikaʻi ʻana i ka wikiwiki o ka nerve conduction.
(3) Nā maʻi metabolic: I ka mālama ʻana i ka hepatitis a me ka cirrhosis, hiki i ka ATP disodium ke hoʻonui i ka hana mitochondrial o nā hepatocytes, hoʻolalelale i ka hoʻoponopono hepatocyte, a hoʻemi i nā pae ALT a me AST; He hopena hoʻomaikaʻi kōkua nō hoʻi ia i nā pilikia maʻi maʻi (e like me peripheral neuropathy).
3. Nā wahi noi e puka mai ana
(1) Pūnaehana hāʻawi lāʻau lapaʻau i manaʻo ʻia: Hiki ke hoʻohana ʻia ka ATP disodium ma ke ʻano he mea hoʻololi lawe, hui pū me nā liposomes a i ʻole nanoparticles, e hoʻokō i ka hāʻawi ʻana i ka lāʻau lapaʻau ma o ka receptor-mediated endocytosis. No ka laʻana, i ka mālama ʻana i ka maʻi tumora, hiki i nā nanomedicine i hoʻololi ʻia ʻo ATP ke hoʻomaikaʻi i ka pono pepehi koho o nā lāʻau lapaʻau chemotherapy ma nā keʻena maʻi maʻi.
(2) Cell moʻomeheu a me biopharmaceuticals: Ma ke ʻano he mea nui o ka moʻomeheu cell moʻomeheu, hiki i ka ATP disodium ke hoʻoikaika i ka ulu a me ka hōʻike protein o nā cell CHO, HEK293 cell, etc., a hoʻohana nui ʻia i ka hana antibody monoclonal.